Org 41841: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9887381 |
| CHEMBL ID | 211405 |
| CHEBI ID | 93615 |
| SCHEMBL ID | 4326072 |
| MeSH ID | M0498452 |
| Synonym |
|---|
| NCGC00165246-01 |
| MLS001065923 |
| smr000486397 |
| 5-amino-n-tert-butyl-4-(3-methoxyphenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide |
| cid_9887381 |
| n-tert-butyl-5-amino-4-(3-methoxyphenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide |
| bdbm50189778 |
| org-41841 |
| org 41841 |
| org41841 |
| CHEMBL211405 , |
| SCHEMBL4326072 |
| HMS2213G07 |
| HMS3355K22 |
| tert-butyl 5-amino-2-methylthio-4-(3-methoxyphenyl)-thieno[2,3-d]pyrimidine-6-carboxamide |
| DVSFSADBOJYPGF-UHFFFAOYSA-N |
| CHEBI:93615 |
| CS-0018422 |
| HY-100271 |
| 5-amino-n-tert-butyl-4-(3-methoxyphenyl)-2-(methylthio)-6-thieno[2,3-d]pyrimidinecarboxamide |
| Q27165307 |
| 5-amino-n-tert-butyl-4-(3-methoxyphenyl)-2-methylsulfanylthieno[2,3-d]pyrimidine-6-carboxamide |
| thieno(2,3-d)pyrimidine-6-carboxamide, 5-amino-n-(1,1-dimethylethyl)-4-(3-methoxyphenyl)-2-(methylthio)- |
| unii-5j2kl52jyj |
| 5j2kl52jyj , |
| 301847-37-0 |
| MS-26868 |
| 5-amino-n-(1,1-dimethylethyl)-4-(3-methoxyphenyl)-2-(methylthio)thieno(2,3-d)pyrimidine-6-carboxamide |
| AKOS040742346 |
| Class | Description |
|---|---|
| pyrimidines | Any compound having a pyrimidine as part of its structure. |
| thienopyrimidine | A class of aromatic heterobicyclic compounds each of which contains a pyrimidine ring ortho fused to a 5-membered thiophene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0013 | 18.0743 | 39.8107 | AID504389 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 44.6684 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 16.6184 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 78.4352 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 78.4352 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 72.6796 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| geminin | Homo sapiens (human) | Potency | 20.5962 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| sentrin-specific protease 1 | Homo sapiens (human) | IC50 (µMol) | 17.1500 | 8.3600 | 13.3160 | 19.7000 | AID651693; AID651697 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thyrotropin receptor | Homo sapiens (human) | EC50 (µMol) | 7.1000 | 0.0900 | 4.7633 | 7.7000 | AID1118932; AID266951 |
| Lutropin-choriogonadotropic hormone receptor | Homo sapiens (human) | EC50 (µMol) | 0.2600 | 0.2200 | 0.2600 | 0.3000 | AID1118936; AID266949 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Thyrotropin receptor | Homo sapiens (human) |
| cell surface | Thyrotropin receptor | Homo sapiens (human) |
| basolateral plasma membrane | Thyrotropin receptor | Homo sapiens (human) |
| receptor complex | Thyrotropin receptor | Homo sapiens (human) |
| plasma membrane | Thyrotropin receptor | Homo sapiens (human) |
| extracellular space | Lutropin-choriogonadotropic hormone receptor | Homo sapiens (human) |
| endosome | Lutropin-choriogonadotropic hormone receptor | Homo sapiens (human) |
| plasma membrane | Lutropin-choriogonadotropic hormone receptor | Homo sapiens (human) |
| centriolar satellite | Lutropin-choriogonadotropic hormone receptor | Homo sapiens (human) |
| receptor complex | Lutropin-choriogonadotropic hormone receptor | Homo sapiens (human) |
| plasma membrane | Lutropin-choriogonadotropic hormone receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1118936 | Agonist activity at LHCGR (unknown origin) | 2011 | MedChemComm, Oct, Volume: 2, Issue:10 | The Synthesis and Evaluation of Dihydroquinazolin-4-ones and Quinazolin-4-ones as Thyroid Stimulating Hormone Receptor Agonists. |
| AID266951 | Agonist activity at TSHR expressed in HEK293 EM cells measured by intracellular cAMP accumulation | 2006 | Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13 | Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. |
| AID266950 | Agonist activity at LHCGR expressed in HEK293 EM cells measured by intracellular cAMP accumulation relative to LH | 2006 | Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13 | Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. |
| AID266949 | Agonist activity at LHCGR expressed in HEK293 EM cells measured by intracellular cAMP accumulation | 2006 | Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13 | Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. |
| AID266952 | Agonist activity at TSHR expressed in HEK293 EM cells measured by intracellular cAMP accumulation relative to TSH | 2006 | Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13 | Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. |
| AID1118932 | Agonist activity at TSHR (unknown origin) | 2011 | MedChemComm, Oct, Volume: 2, Issue:10 | The Synthesis and Evaluation of Dihydroquinazolin-4-ones and Quinazolin-4-ones as Thyroid Stimulating Hormone Receptor Agonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||